Ritholtz Wealth Management Aeglea Bio Therapeutics, Inc. Transaction History

Ritholtz Wealth Management

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 Apr 19, 2023	SELL	$0.29 - $0.61 $10,067 - $21,176	-34,716 Reduced 45.39%	41,774 $12,000
Q3 2021 Oct 14, 2021	SELL	$6.03 - $7.95 $591,880 - $780,340	-98,156 Reduced 56.2%	76,490 $608,000
Q2 2020 Jul 15, 2020	SELL	$4.01 - $11.04 $200,500 - $552,000	-50,000 Reduced 22.26%	174,646 $1.62 Million
Q1 2020 Apr 09, 2020	SELL	$3.51 - $8.48 $70,200 - $169,600	-20,000 Reduced 8.18%	224,646 $1.05 Million
Q4 2019 Jan 17, 2020	SELL	$7.23 - $8.55 $144,600 - $171,000	-20,000 Reduced 7.56%	244,646 $1.87 Million
Q3 2019 Oct 17, 2019	SELL	$6.42 - $9.0 $166,200 - $232,992	-25,888 Reduced 8.91%	264,646 $2.04 Million
Q4 2018 Jan 18, 2019	BUY	$6.51 - $10.19 $1.89 Million - $2.96 Million	290,534 New	290,534 $2.18 Million

241K

Ticker AGLE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,172,500
Market Cap $1.69B
Description
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy f...

Get notified when there are updates to the investment portfolio of Ritholtz Wealth Management, based on Form 13F filings with the SEC.

Stay updated on Ritholtz Wealth Management with notifications on news.